Bispecific Antibodies in the Treatment of Hematologic Malignancies

被引：51

作者：

Duell, Johannes ^{[1
]}

Lammers, Philip E. ^{[2
]}

Djuretic, Ivana ^{[3
]}

Chunyk, Allison G. ^{[4
]}

Alekar, Shilpa ^{[4
]}

Jacobs, Ira ^{[5
]}

Gill, Saar ^{[6
,7
]}

机构：

[1] Univ Klinikum Wurzburg, Dept Internal Med 2, Wurzburg, Germany

[2] Baptist Canc Ctr, Memphis, TN USA

[3] Pfizer Inc, San Francisco, CA USA

[4] Pfizer Inc, La Jolla, CA USA

[5] Pfizer Inc, New York, NY 10017 USA

[6] Univ Penn, Blood & Marrow Transplantat Program, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[7] Univ Penn, Div Hematol & Oncol, Perelman Sch Med, Philadelphia, PA 19104 USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2019年 / 106卷 / 04期

关键词：

ACUTE LYMPHOBLASTIC-LEUKEMIA; CYTOKINE RELEASE SYNDROME; CAR T-CELLS; CLINICAL DEVELOPMENT; BLINATUMOMAB; THERAPY; RESISTANCE; DEPLETION; EFFICACY; SAFETY;

D O I：

10.1002/cpt.1396

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Monoclonal antibody therapies are an important approach for the treatment of hematologic malignancies, but typically show low single-agent activity. Bispecific antibodies, however, redirect immune cells to the tumor for subsequent lysis, and preclinical and accruing clinical data support single-agent efficacy of these agents in hematologic malignancies, presaging an exciting era in the development of novel bispecific formats. This review discusses recent developments in this area, highlighting the challenges in delivering effective immunotherapies for patients.

引用

页码：781 / 791

页数：11

共 50 条

[1] Bispecific antibodies for the treatment of hematologic malignancies: The magic is T-cell redirection
Shouse, Geoffrey
BLOOD REVIEWS, 2025, 69
[2] Current landscape of CD3 bispecific antibodies in hematologic malignancies
Kassner, Joshua
Abdellatif, Basma
Yamshon, Samuel
Monge, Jorge
Kaner, Justin
TRENDS IN CANCER, 2024, 10 (08) : 708 - 732
[3] Bispecific antibodies in the treatment of hematologic neoplasms and solid tumors
Zhou, Xiang
Waldschmidt, Johannes M.
Einsele, Hermann
ONKOLOGIE, 2025,
[4] Bispecific Antibodies in Hematologic Malignancies: When, to Whom, and How Should Be Best Used?
Roberta Demichelis-Gómez
Daniela Pérez-Sámano
Christianne Bourlon
Current Oncology Reports, 2019, 21
[5] Bispecific Antibodies in Hematologic Malignancies: When, to Whom, and How Should Be Best Used?
Demichelis-Gomez, Roberta
Perez-Samano, Daniela
Bourlon, Christianne
CURRENT ONCOLOGY REPORTS, 2019, 21 (02)
[6] Antibodies and hematologic malignancies
Smith, Mitchell R.
CANCER JOURNAL, 2008, 14 (03): : 184 - 190
[7] Bispecific antibodies in haematological malignancies
Viardot, Andreas
Bargou, Ralf
CANCER TREATMENT REVIEWS, 2018, 65 : 87 - 95
[8] HLA class II antibodies in the treatment of hematologic malignancies
Dechant, M
Bruenke, J
Valerius, T
SEMINARS IN ONCOLOGY, 2003, 30 (04) : 465 - 475
[9] Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies
Antonarelli, Gabriele
Giugliano, Federica
Corti, Chiara
Repetto, Matteo
Tarantino, Paolo
Curigliano, Giuseppe
PHARMACEUTICALS, 2021, 14 (09)
[10] A novel in vitro approach elucidates a new mode of cytotoxic action of bispecific antibodies on hematologic malignancies
Primo, Daniel
Hernandez, Pilar
Gorrochategui, Julian
Vicente, Maria L.
Martinez-Cuadron, David
Montesinos, Pau
Martinez-Lopez, Joaquin
Ballesteros, Joan
MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)

← 1 2 3 4 5 →